A novel method for the preparation of no-carrier-added (nca) complexes [99mTc(CO)3L] (L = diethylenetriamine or picolylamine-N-acetic acid) is described. The ligands were covalently bound to a solid support of organic polymers via formation of a tertiary amine from the chelating unit. This C-N bond to the solid phase is selectively cleaved during the formation of the technetium complexes by intramolecular nucleophilic attack of a remaining hydroxy ligand to the alpha-carbon. The complex [99mTc(CO)3L] is released into solution while uncomplexed ligand and uncleaved complex remain solid-phase bound. High specific activity technetium complexes can then be isolated by simple filtration. Cleavage yield depends on temperature, pH, and ligand. Up to 50% release from the solid phase could be achieved under optimized conditions. Corresponding to the 99mTc concentration, free ligand is present in concentrations lower than 10(-7) M. If a targeting vector is conjugated to these ligands, no-carrier-added radiopharmaceuticals can be prepared in that way.
A novel method for the preparation of no-carrier-added (nca) complexes [99mTc(n class="Chemical">CO)3L] (L = diethylenetriamine or picolylamine-N-acetic acid) is described. The ligands were covalently bound to a solid support of organic polymers via formation of a tertiary amine from the chelating unit. This C-N bond to the solid phase is selectively cleaved during the formation of the technetium complexes by intramolecular nucleophilic attack of a remaining hydroxy ligand to the alpha-carbon. The complex [99mTc(CO)3L] is released into solution while uncomplexed ligand and uncleaved complex remain solid-phase bound. High specific activity technetium complexes can then be isolated by simple filtration. Cleavage yield depends on temperature, pH, and ligand. Up to 50% release from the solid phase could be achieved under optimized conditions. Corresponding to the 99mTc concentration, free ligand is present in concentrations lower than 10(-7) M. If a targeting vector is conjugated to these ligands, no-carrier-added radiopharmaceuticals can be prepared in that way.
Authors: Malgorzata Lipowska; Haiyang He; Xiaolong Xu; Andrew T Taylor; Patricia A Marzilli; Luigi G Marzilli Journal: Inorg Chem Date: 2010-04-05 Impact factor: 5.165
Authors: Richard S Herrick; Christopher J Ziegler; Kathryn L Kennedy; Calvin Luu; James T Engle Journal: Eur J Inorg Chem Date: 2013-03-01 Impact factor: 2.524
Authors: Malgorzata Lipowska; Haiyang He; Eugene Malveaux; Xiaolong Xu; Luigi G Marzilli; Andrew Taylor Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Stephanie R Lane; Bhadrasetty Veerendra; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Silvia S Jurisson; Charles J Smith Journal: Nucl Med Biol Date: 2008-04 Impact factor: 2.408